Join us to examine the FDA's New Paradigm on One-Day Inspections.

The U.S. Food and Drug Administration (FDA) has introduced a pilot program for one-day inspectional assessments, signaling a meaningful evolution in its regulatory oversight strategy. Launched in April 2026, this initiative is part of a broader effort to enhance the efficiency, agility, and risk-based focus of FDA inspections across regulated industries, including pharmaceuticals, biologics, medical products, food, and clinical research.
In this one-hour webinar, the structure and objectives of the FDA’s new program, along with key insights and lessons learned from publicly available information during its inaugural year, will be examined.  The session will also explore potential industry concerns associated with one-day assessments, including operational, compliance, and strategic implications.

Additionally, attendees will gain perspective from a former FDA director, who will share expert commentary on the program’s impact, practical considerations for industry, and expectations for how this approach may shape the future of regulatory inspections.

Speaker: Eric Pittman, MBA
Eric is a seasoned professional with more than 20 years of experience at the U.S. Food and Drug Administration, where he conducted extensive inspections across the pharmaceutical, medical device, Bioresearch Monitoring (BIMO), and food sectors. Throughout his FDA tenure, he played a key role in developing inspectional policies and implementing new programs driven by emerging laws and regulations. Eric concluded his FDA career as the Division Director for Bioresearch Monitoring.
He also represented the United States at the Organization for Economic Cooperation and Development (OECD) Working Party on Good Laboratory Practices, headquartered in Paris, France. A frequent keynote speaker, Eric has presented at numerous national and international conferences. For ten years, he served as Editor-in-Chief of the FDA’s Investigations Operations Manual, the agency’s primary field inspection reference.
Beyond his government service, Eric has held leadership roles in both the pharmaceutical and medical device industries, including positions within top-tier companies in each sector. He currently serves as Vice President of Quality Assurance and Regulatory Affairs at Project Farma, a PerkinElmer company.

This one-hour, high‑impact session is designed for professionals in Regulatory Affairs, Quality Assurance, Quality Control, Manufacturing, Validation, and Compliance who need to stay ahead of the impact of this new pilot inspection program on the industry.

Sponsored by RA/QA Program, Temple University, School of Pharmacy.